|
George W. Vetrovec, MDCertificationsEmeritus Professor of Medicine University / Hospital AffiliationVCU Pauley Heart Center; Virginia Commonwealth University Additional Titles and RolesExecutive Chairperson of A-CURE Focus AreasInterventional Cardiology, Clinical Research AboutDr. George W. Vetrovec, MACC and MSCAI is an Emeritus Professor of Medicine at VCU Pauley Heart Center at VCU in Richmond, Virginia. His experience covers four decades of interventional cardiology and his research has focused on optimal management of ischemic heart disease particularly involving high risk PCI, most often with reduced Left Ventricular function. He has extensive experience in new cardiovascular device innovation and evaluation. During his career, He has served on the Boards of the AHA, ACC and SCAI, including SCAI President. Dr. Vetrovec remains actively in interventional cardiology, as a consultant, teacher as well as serving on multiple editorial boards and is the Editorial Lead for the Angiography and Interventional Section of ACC.org.
|
Manuscripts & Publications
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 TrialThe SYMPLICITY HTN-3 (Renal Denervation in Patients With Uncontrolled Hypertension) trial showed the safety but not efficacy of the Symplicity system (Medtronic, Santa Rosa, CA, USA) at 6 months follow-up in patients with treatment-resistant hypertension. This final report presents the 36-month follow-up results.
|
|
2022 ACC Health Policy Statement on Career Flexibility in Cardiology: A Report of the American College of Cardiology Solution Set Oversight CommitteeThe American College of Cardiology (ACC) has a long history of developing documents (eg, decision pathways, health policy statements [HPS], appropriate use criteria) to provide members with guidance on both clinical and nonclinical topics relevant to cardiovascular (CV) care. In most circumstances, these documents have been created to complement clinical practice guidelines and to inform clinicians about areas where evidence is new and evolving or where sufficient data is more limited. Despite this, numerous gaps persist, highlighting the need for more streamlined and efficient processes to implement best practices in patient care.
|
|
Strategies for Reducing Vascular and Bleeding Risk for Percutaneous Left Ventricular Assist Device-supported High-risk Percutaneous Coronary InterventionIn patients at high risk for haemodynamic instability during percutaneous coronary intervention (PCI), practitioners are increasingly opting for prophylactic mechanical circulatory support, such as the Impella® heart pump (Abiomed, Danvers, MA, USA).
|